{"protocolSection": {"identificationModule": {"nctId": "NCT02194699", "orgStudyIdInfo": {"id": "D2210C00008"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma", "officialTitle": "A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting \u03b22-Agonist", "acronym": "STRATOS2"}, "statusModule": {"statusVerifiedDate": "2018-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-10-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-05-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-09-21", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-07-17", "studyFirstSubmitQcDate": "2014-07-17", "studyFirstPostDateStruct": {"date": "2014-07-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-02-23", "resultsFirstSubmitQcDate": "2018-02-23", "resultsFirstPostDateStruct": {"date": "2018-03-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-04-13", "lastUpdatePostDateStruct": {"date": "2018-05-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting \u03b22-Agonist", "detailedDescription": "This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate efficacy and safety of tralokinumab administered subcutaneously in subjects with uncontrolled asthma on inhaled corticosteroid plus long-acting \u03b22-agonist and having a history of asthma exacerbations. Approximately 770 subjects will be randomized globally. Subjects will receive tralokinumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period."}, "conditionsModule": {"conditions": ["Uncontrolled Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 856, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tralokinumab", "type": "EXPERIMENTAL", "description": "Tralokinumab subcutaneous injection", "interventionNames": ["Biological: Experimental: Tralokinumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo subcutaneous injection", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Experimental: Tralokinumab", "description": "Tralokinumab subcutaneous injection", "armGroupLabels": ["Tralokinumab"]}, {"type": "OTHER", "name": "Placebo", "description": "Placebo subcutaneous injection", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Annualised Asthma Exacerbation Rate (AAER) up to Week 52", "description": "Asthma exacerbation was defined as a worsening of asthma that led to any of the following:\n\n* Use of systemic corticosteroids for at least 3 days; a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of systemic corticosteroids.\n* An emergency room (ER) or urgent care (UC) visit (defined as evaluation and treatment for \\<24 hours in an ER or UC centre) due to asthma that required systemic corticosteroids (see above).\n* An inpatient hospitalisation (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for \u226524 hours) due to asthma.\n\nAAER = number of exacerbations\\*365.25 / (follow-up date - date of randomisation + 1) (where maximum follow-up time for a patient was approximately 52 weeks).\n\nAAER in the tralokinumab group was compared to that seen in the placebo group up to Week 52 using a negative binomial model; rate ratios and rate reductions are both presented for comparative statistical analyses.", "timeFrame": "Baseline (Week 0) up to Week 52"}], "secondaryOutcomes": [{"measure": "Percent Change From Baseline to Week 52 in Pre-dose/Pre-bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV1)", "description": "Lung function was assessed by FEV1 which was measured by spirometry. Spirometry was performed by the Investigator or authorised delegate according to American Thoracic Society/European Respiratory Society guidelines. The mean percent change from baseline in pre-BD FEV1 at Week 52 is presented.", "timeFrame": "Baseline (Week 0) and Week 52"}, {"measure": "Change From Baseline to Week 52 in Total Asthma Symptom Score (Bi-weekly Means)", "description": "Asthma symptoms during night-time and daytime were recorded by the patient each morning and evening in the Asthma Daily Diary. Symptoms were recorded using a 4-point response scale, which ranged from 0 to 3, where 0 indicated no asthma symptoms. Asthma symptom daytime score (recorded in the evening), night-time score (recorded in the morning), and total score were calculated separately. The daily asthma symptom total score was calculated by taking the sum of the night-time and daytime asthma symptom scores recorded each day, ranging from 0 to 6. A lower symptom score indicated a better outcome. The change from baseline in bi-weekly mean daily asthma symptom total score is presented.", "timeFrame": "Baseline (Week 0) and Week 52"}, {"measure": "Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score", "description": "The AQLQ(S)+12 is a questionnaire that measures health-related quality of life for patients with asthma aged 12 and older. The questionnaire comprises 32 questions and has 4 separate domains (asthma symptoms, activity limitations, emotional function and environmental stimuli). Patients were asked to recall their experiences during the previous 2 weeks and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The total score was calculated as the mean response to all questions, ranging from 1 (severe impairment) to 7 (no impairment). Individual AQLQ(S)+12 total score changes of \u22650.5 were considered to be clinically meaningful. The mean change from baseline in AQLQ(S)+12 score at Week 52 is presented.", "timeFrame": "Baseline (Week 0) and Week 52"}, {"measure": "Change From Baseline to Week 52 in Asthma Control Questionnaire-6 (ACQ-6) Score", "description": "The ACQ-6 questionnaire is a shortened version of the ACQ (omitting FEV1 measurement) that assesses asthma symptoms (night-time awakenings, symptoms on waking, activity limitation, dyspnoea, wheezing) and rescue short-acting \u03b22-agonists medication use during the past week. Questions were weighted equally and scored on a 7-point scale from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of \u22640.75 indicate well-controlled asthma, scores between 0.75 and \u22641.5 indicate partly controlled asthma and a score \\>1.5 indicates not well-controlled asthma. Individual changes of at least 0.5 were considered to be clinically meaningful. The mean change from baseline in ACQ-6 score at Week 52 is presented.", "timeFrame": "Baseline (Week 0) and Week 52"}, {"measure": "AAER Associated With an ER/UC Visit, or a Hospitalisation up to Week 52", "description": "The annual rate of exacerbations associated with an ER/UC visit or hospitalisation up to Week 52 are presented for non-adjudicated data (i.e. events assessed by the Investigator and recorded in the electronic case report form).\n\nAAER = number of exacerbations\\*365.25 / (follow-up date - date of randomisation + 1) (where maximum follow-up time for a patient was approximately 52 weeks).", "timeFrame": "Baseline (Week 0) up to Week 52"}, {"measure": "Change From Baseline in European Quality of Life - 5 Dimension 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Scores at Week 52", "description": "The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The patient was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The questionnaire also included a VAS, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state. The mean change from baseline in EQ-5D-5L VAS scores at Week 52 is presented.", "timeFrame": "Baseline (Week 0) and Week 52"}, {"measure": "Change From Baseline in Total Asthma Rescue Medication Use at Week 52 (Bi-weekly Means)", "description": "Salbutamol, albuterol or levalbuterol were used as rescue medication during the study in the event of a worsening of asthma symptoms. Rescue medication use was measured by the bi-weekly mean number of inhalations (puffs) per day, calculated as: total morning puffs + total evening puffs + 2\\*(total morning nebuliser use + total evening nebuliser use)/ total number of days with data in bi-weekly period. The change from baseline in bi-weekly mean total asthma rescue medication use at Week 52 is presented.", "timeFrame": "Baseline (Week 0) and Week 52"}, {"measure": "Change From Baseline in Home Peak Expiratory Flow (PEF) (Morning and Evening) at Week 52", "description": "Home PEF testing was performed by the patient using an electronic, hand-held spirometer (peak flow meter) and was performed in the morning upon awakening (prior to taking their morning asthma controller) and in the evening at bedtime (prior to taking their evening asthma controller). The mean change from baseline in home PEF values at Week 52 are presented separately for morning and evening.", "timeFrame": "Baseline (Week 0) and Week 52"}, {"measure": "Change From Baseline in Night-time Awakenings Due to Asthma Requiring Rescue Medication Use at Week 52 (Bi-weekly Means [Percentage])", "description": "The patient captured night-time awakenings (yes/no) and the use of rescue medication during these awakenings (yes/no) each morning in the Asthma Daily Diary. Night-time awakenings (percentage) was defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data. The change from baseline in bi-weekly means (percentage) night-time awakenings due to asthma requiring rescue medication use at Week 52 is presented.", "timeFrame": "Baseline (Week 0) and Week 52"}, {"measure": "Number of Patients With \u22651 Asthma Exacerbation up to Week 52", "description": "The number of patients with \u22651 asthma exacerbation up to Week 52 is presented.", "timeFrame": "Baseline (Week 0) up to Week 52"}, {"measure": "Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questions (WPAI+CIQ): Productivity Loss at Week 52", "description": "The WPAI+CIQ consists of questions about how asthma and asthma-related issues impact a patient's ability to work, attend classes and perform regular daily activities. The questionnaire contains 10 questions relating to the patient's experience over the previous 7 days.\n\nThe WPAI+CIQ outcomes for productivity loss are presented separately for those currently employed and for those currently in school and are expressed as mean productivity loss (percentage) at Week 52, with higher numbers indicating less productivity.\n\nWork Productivity Loss = {Q2/(Q2+Q4)+\\[(1-Q2/(Q2+Q4))x(Q5/10)\\]}\\*100 (Absenteeism = Q2/(Q2+Q4)\\*100; Presenteeism = (Q5/10)\\*100).\n\nClass Productivity Loss = {Q7/(Q7+Q8) + \\[(1-Q7/(Q7+Q8))x(Q9/10)\\]}\\*100 (Absenteeism = Q7/(Q7+Q8)\\*100; Presenteeism = (Q9/10)\\*100).\n\nNote: QX refers to response to question number X on WPAI+CIQ questionnaire.", "timeFrame": "At Week 52"}, {"measure": "WPAI+CIQ: Activity Impairment at Week 52", "description": "The WPAI+CIQ consists of questions about how asthma and asthma-related issues impact a patient's ability to work, attend classes and perform regular daily activities. The questionnaire contains 10 questions relating to the patient's experience over the previous 7 days.\n\nThe WPAI+CIQ outcomes for activity impairment are presented separately for those currently employed and for those currently in school and are expressed as mean impairment percentages at Week 52, with higher numbers indicating greater impairment.\n\nActivity impairment = (Q10/10)\\*100. Note: QX refers to response to question number X on WPAI+CIQ questionnaire.", "timeFrame": "At Week 52"}, {"measure": "Asthma-related Healthcare Encounters by Type up to Week 52", "description": "Broad-based healthcare utilisation asthma-related event information was collected by the Investigator/authorised delegate at each visit. At Visit 1, healthcare resource utilisation information was collected with a 1-year recall period; subsequent visits collected information with a recall period of 'since the last scheduled visit'. Total number of times the healthcare encounter occurred was calculated across all patients for each of the following categories:\n\n* Ambulance transport,\n* Emergency room visits,\n* Unscheduled outpatient visits (visit to specialist and/or visit to primary healthcare physician and/or other healthcare visit),\n* Home visits (home visit, physician and/or other healthcare professional),\n* Telephone calls (telephone calls to physician and/or nurse), and\n* Advanced pulmonary function test.", "timeFrame": "Baseline (Week 0) up to Week 52"}, {"measure": "Asthma-related Healthcare Encounters by Type up to Week 52: Hospitalisations", "description": "Broad-based healthcare utilisation asthma-related event information was collected by the Investigator/authorised delegate at each visit. At Visit 1, healthcare resource utilisation information was collected with a 1-year recall period; subsequent visits collected information with a recall period of 'since the last scheduled visit'. Total number of days spent in hospital was calculated across all patients for the following healthcare encounter category:\n\n\u2022 Hospitalisations (hospitalisations, intensive care and/or general care).", "timeFrame": "Baseline (Week 0) up to Week 52"}, {"measure": "Asthma-related Healthcare Encounters by Type up to Week 52: Spirometry", "description": "Broad-based healthcare utilisation asthma-related event information was collected by the Investigator/authorised delegate at each visit. At Visit 1, healthcare resource utilisation information was collected with a 1-year recall period; subsequent visits collected information with a recall period of 'since the last scheduled visit'. Total number of assessments was calculated across all patients for the following healthcare encounter category:\n\n\u2022 Spirometry.", "timeFrame": "Baseline (Week 0) up to Week 52"}, {"measure": "Serum Trough Concentration (Ctrough) of Tralokinumab During the Treatment Period up to Week 72", "description": "To evaluate the pharmacokinetics (PK), pre-dose blood samples were collected at each visit and tralokinumab concentrations in serum were determined. Mean Ctrough concentrations are presented at each indicated visit up to Week 72.", "timeFrame": "Blood samples were collected pre-dose at Baseline (Week 0), and at Week 2, Week 8, Week 26, Week 56 (follow-up) and Week 72 (follow-up)"}, {"measure": "Incidence Rate of Positive Anti-drug Antibodies (ADAs) Including the Characterization of Their Neutralizing Potential", "description": "Assessments of ADA were performed using a tiered approach (screening, confirmatory and titering assays). Confirmed ADA positive samples were also tested for the presence of neutralising antibodies (nAb). ADA prevalence was defined as proportion of the study population having drug-reactive antibodies at any point in time. ADA incidence (treatment-emergent ADA) was defined as the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA. Persistently positive was defined as positive at \u22652 post-baseline assessments (with \u226516 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher level following drug administration. Note: 'positive' is denoted by 'pos' in some category titles.", "timeFrame": "Baseline (Week 0), Week 26, Week 56 (follow-up) and Week 72 (follow-up)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 12 -75\n2. Documented physician-diagnosed asthma.\n3. Documented treatment with ICS at a total daily dose corresponding to \u2265500\u03bcg fluticasone propionate dry powder formulation equivalents) and a LABA\n4. Morning pre-BD FEV1 value of \u226540 and \\<80% value (\\<90% for patients 12 to 17 years of age) of their PNV.\n5. Post-BD reversibility of \u226512% and \u2265200 mL in FEV1\n6. ACQ-6 score \u22651.5\n\nExclusion Criteria:\n\n1. Pulmonary disease other than asthma\n2. History of anaphylaxis following any biologic therapy\n3. Hepatitis B, C or HIV\n4. Pregnant or breastfeeding\n5. History of cancer\n6. Current tobacco smoking or a history of tobacco smoking for \u2265 10 pack-years\n7. Previous receipt of tralokinumab", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Christopher Brightling, MD", "affiliation": "Institute for Lung Health, United Kingdom", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Birmingham", "state": "Alabama", "zip": "35294", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Research Site", "city": "Hoover", "state": "Alabama", "zip": "35244", "country": "United States", "geoPoint": {"lat": 33.40539, "lon": -86.81138}}, {"facility": "Research Site", "city": "Huntsville", "state": "Alabama", "zip": "35803", "country": "United States", "geoPoint": {"lat": 34.7304, "lon": -86.58594}}, {"facility": "Research Site", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Research Site", "city": "Little Rock", "state": "Arkansas", "zip": "72209", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Research Site", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Research Site", "city": "Buena Park", "state": "California", "zip": "90620", "country": "United States", "geoPoint": {"lat": 33.86751, "lon": -117.99812}}, {"facility": "Research Site", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Research Site", "city": "Lakewood", "state": "California", "zip": "90805", "country": "United States", "geoPoint": {"lat": 33.85363, "lon": -118.13396}}, {"facility": "Research Site", "city": "Lomita", "state": "California", "zip": "90717", "country": "United States", "geoPoint": {"lat": 33.79224, "lon": -118.31507}}, {"facility": "Research Site", "city": "Northridge", "state": "California", "zip": "91324", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Research Site", "city": "Palmdale", "state": "California", "zip": "93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Research Site", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "Research Site", "city": "Sacramento", "state": "California", "zip": "95819", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Research Site", "city": "San Francisco", "state": "California", "zip": "94102", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "Research Site", "city": "Thousand Oaks", "state": "California", "zip": "91360", "country": "United States", "geoPoint": {"lat": 34.17056, "lon": -118.83759}}, {"facility": "Research Site", "city": "Ventura", "state": "California", "zip": "93003-3099", "country": "United States", "geoPoint": {"lat": 34.27834, "lon": -119.29317}}, {"facility": "Research Site", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Research Site", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Research Site", "city": "Celebration", "state": "Florida", "zip": "34747", "country": "United States", "geoPoint": {"lat": 28.32529, "lon": -81.53313}}, {"facility": "Research Site", "city": "DeLand", "state": "Florida", "zip": "32720", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"facility": "Research Site", "city": "Gainesville", "state": "Florida", "zip": "32607", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Research Site", "city": "Hialeah", "state": "Florida", "zip": "33016", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33126", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33142", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33144", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33155", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33165", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33176", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "New Port Richey", "state": "Florida", "zip": "34653", "country": "United States", "geoPoint": {"lat": 28.24418, "lon": -82.71927}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32819", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Palmetto Bay", "state": "Florida", "zip": "33157", "country": "United States", "geoPoint": {"lat": 25.62177, "lon": -80.32477}}, {"facility": "Research Site", "city": "Port Charlotte", "state": "Florida", "zip": "33952", "country": "United States", "geoPoint": {"lat": 26.97617, "lon": -82.09064}}, {"facility": "Research Site", "city": "Saint Petersburg", "state": "Florida", "zip": "33710", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "zip": "33607", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "Columbus", "state": "Georgia", "zip": "31904", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "Research Site", "city": "Gainesville", "state": "Georgia", "zip": "30501", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Research Site", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Research Site", "city": "Eagle", "state": "Idaho", "zip": "83616", "country": "United States", "geoPoint": {"lat": 43.69544, "lon": -116.35401}}, {"facility": "Research Site", "city": "Evergreen Park", "state": "Illinois", "zip": "60805", "country": "United States", "geoPoint": {"lat": 41.72059, "lon": -87.70172}}, {"facility": "Research Site", "city": "Kenilworth", "state": "Illinois", "zip": "60043", "country": "United States", "geoPoint": {"lat": 42.08586, "lon": -87.71756}}, {"facility": "Research Site", "city": "Peoria", "state": "Illinois", "zip": "61602", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Research Site", "city": "White Marsh", "state": "Maryland", "zip": "21162", "country": "United States", "geoPoint": {"lat": 39.38372, "lon": -76.43218}}, {"facility": "Research Site", "city": "Fall River", "state": "Massachusetts", "zip": "02720", "country": "United States", "geoPoint": {"lat": 41.70149, "lon": -71.15505}}, {"facility": "Research Site", "city": "Reno", "state": "Nevada", "zip": "89503", "country": "United States", "geoPoint": {"lat": 39.52963, "lon": -119.8138}}, {"facility": "Research Site", "city": "Northfield", "state": "New Jersey", "zip": "08225", "country": "United States", "geoPoint": {"lat": 39.37039, "lon": -74.55015}}, {"facility": "Research Site", "city": "Ocean City", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "Research Site", "city": "Teaneck", "state": "New Jersey", "zip": "07666", "country": "United States", "geoPoint": {"lat": 40.8976, "lon": -74.01597}}, {"facility": "Research Site", "city": "Toms River", "state": "New Jersey", "zip": "08755", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Research Site", "city": "Verona", "state": "New Jersey", "zip": "07044", "country": "United States", "geoPoint": {"lat": 40.82982, "lon": -74.24015}}, {"facility": "Research Site", "city": "Albuquerque", "state": "New Mexico", "zip": "87131", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10459", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Larchmont", "state": "New York", "zip": "10538", "country": "United States", "geoPoint": {"lat": 40.92788, "lon": -73.7518}}, {"facility": "Research Site", "city": "Wappingers Falls", "state": "New York", "zip": "12590", "country": "United States", "geoPoint": {"lat": 41.59648, "lon": -73.91097}}, {"facility": "Research Site", "city": "Burlington", "state": "North Carolina", "zip": "27215", "country": "United States", "geoPoint": {"lat": 36.09569, "lon": -79.4378}}, {"facility": "Research Site", "city": "Charlotte", "state": "North Carolina", "zip": "28205", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Research Site", "city": "Greensboro", "state": "North Carolina", "zip": "27410", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Research Site", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Tulsa", "state": "Oklahoma", "zip": "74135", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Research Site", "city": "Tulsa", "state": "Oklahoma", "zip": "74136", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Research Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Research Site", "city": "Rock Hill", "state": "South Carolina", "zip": "29732", "country": "United States", "geoPoint": {"lat": 34.92487, "lon": -81.02508}}, {"facility": "Research Site", "city": "Arlington", "state": "Texas", "zip": "76018", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "Research Site", "city": "Baytown", "state": "Texas", "zip": "77521", "country": "United States", "geoPoint": {"lat": 29.7355, "lon": -94.97743}}, {"facility": "Research Site", "city": "Frisco", "state": "Texas", "zip": "75034", "country": "United States", "geoPoint": {"lat": 33.15067, "lon": -96.82361}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77043", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77083", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77089", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Kingwood", "state": "Texas", "zip": "77339", "country": "United States", "geoPoint": {"lat": 30.03355, "lon": -95.26104}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78212", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Orem", "state": "Utah", "zip": "84058", "country": "United States", "geoPoint": {"lat": 40.2969, "lon": -111.69465}}, {"facility": "Research Site", "city": "Salt Lake City", "state": "Utah", "zip": "84132", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "Research Site", "city": "Fairfax", "state": "Virginia", "zip": "22030", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Research Site", "city": "Greenfield", "state": "Wisconsin", "zip": "53228", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Research Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53226", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Research Site", "city": "Sherwood Park", "state": "Alberta", "zip": "T8L 0N2", "country": "Canada", "geoPoint": {"lat": 53.51684, "lon": -113.3187}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Ajax", "state": "Ontario", "zip": "L1S 2J5", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Research Site", "city": "Ajax", "state": "Ontario", "zip": "L1Z 0M1", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Research Site", "city": "Burlington", "state": "Ontario", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Research Site", "city": "London", "state": "Ontario", "zip": "N6A 1V2", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "Research Site", "city": "Mississauga", "state": "Ontario", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "zip": "M4V 1R2", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "Windsor", "state": "Ontario", "zip": "N8X 5A6", "country": "Canada", "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H4J 1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Quebec City", "state": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "St Charles Borromee", "state": "Quebec", "zip": "J6E 2B4", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -73.46586}}, {"facility": "Research Site", "city": "Saskatoon", "state": "Saskatchewan", "zip": "S7N 0W8", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1G 3Y8", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Santiago", "zip": "7500698", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Santiago", "zip": "7750495", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Santiago", "zip": "7980378", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Santiago", "zip": "8380453", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Santiago", "zip": "8910131", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Talcahuano", "zip": "4270918", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "Research Site", "city": "Brandys nad Labem", "zip": "250 01", "country": "Czechia", "geoPoint": {"lat": 50.18356, "lon": 14.67244}}, {"facility": "Research Site", "city": "Jindrichuv Hradec", "zip": "377 01", "country": "Czechia", "geoPoint": {"lat": 49.14404, "lon": 15.00301}}, {"facility": "Research Site", "city": "Praha 10 - Strasnice", "zip": "100 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Praha", "zip": "130 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Rokycany", "zip": "337 22", "country": "Czechia", "geoPoint": {"lat": 49.7427, "lon": 13.59459}}, {"facility": "Research Site", "city": "Teplice", "zip": "415 01", "country": "Czechia", "geoPoint": {"lat": 50.6404, "lon": 13.82451}}, {"facility": "Research Site", "city": "Catania", "zip": "95123", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Research Site", "city": "Genova", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "Research Site", "city": "Legnago", "zip": "37045", "country": "Italy", "geoPoint": {"lat": 45.19365, "lon": 11.30227}}, {"facility": "Research Site", "city": "Messina", "zip": "98124", "country": "Italy", "geoPoint": {"lat": 38.19394, "lon": 15.55256}}, {"facility": "Research Site", "city": "Milano", "zip": "20122", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Research Site", "city": "Napoli", "zip": "80131", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "Research Site", "city": "Palermo", "zip": "90146", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Research Site", "city": "Pisa", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Research Site", "city": "Salerno", "zip": "84131", "country": "Italy", "geoPoint": {"lat": 40.67545, "lon": 14.79328}}, {"facility": "Research Site", "city": "Verona", "zip": "37126", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}, {"facility": "Research Site", "city": "Asahi-shi", "zip": "289-2511", "country": "Japan", "geoPoint": {"lat": 35.71667, "lon": 140.65}}, {"facility": "Research Site", "city": "Chuo-ku", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Fukui-shi", "zip": "910-8526", "country": "Japan", "geoPoint": {"lat": 36.06443, "lon": 136.22257}}, {"facility": "Research Site", "city": "Fukushima-shi", "zip": "960-1295", "country": "Japan", "geoPoint": {"lat": 37.75, "lon": 140.46667}}, {"facility": "Research Site", "city": "Habikino-shi", "zip": "583-8588", "country": "Japan", "geoPoint": {"lat": 34.55276, "lon": 135.59097}}, {"facility": "Research Site", "city": "Himeji-shi", "zip": "672-8064", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Research Site", "city": "Hiroshima-shi", "zip": "732-0052", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Research Site", "city": "Itabashi-ku", "zip": "173-8610", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Research Site", "city": "Izumo-shi", "zip": "693-8501", "country": "Japan", "geoPoint": {"lat": 35.36667, "lon": 132.76667}}, {"facility": "Research Site", "city": "Kagoshima-shi", "zip": "890-0064", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Research Site", "city": "Kanazawa", "zip": "920-8641", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"facility": "Research Site", "city": "Kanuma-shi", "zip": "322-0036", "country": "Japan", "geoPoint": {"lat": 36.55, "lon": 139.73333}}, {"facility": "Research Site", "city": "Kasuga-shi", "zip": "816-0813", "country": "Japan"}, {"facility": "Research Site", "city": "Kishiwada-shi", "zip": "596-8501", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Research Site", "city": "Kobe-shi", "zip": "650-0047", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Research Site", "city": "Kobe-shi", "zip": "653-0013", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Research Site", "city": "Kochi-shi", "zip": "780-8077", "country": "Japan", "geoPoint": {"lat": 33.55, "lon": 133.53333}}, {"facility": "Research Site", "city": "Maebashi-shi", "zip": "371-8511", "country": "Japan", "geoPoint": {"lat": 36.4, "lon": 139.08333}}, {"facility": "Research Site", "city": "Matsue-shi", "zip": "690-8556", "country": "Japan", "geoPoint": {"lat": 35.48333, "lon": 133.05}}, {"facility": "Research Site", "city": "Matsusaka-shi", "zip": "515-8544", "country": "Japan"}, {"facility": "Research Site", "city": "Meguro-ku", "zip": "153-8515", "country": "Japan", "geoPoint": {"lat": 42.12755, "lon": 143.31736}}, {"facility": "Research Site", "city": "Minato-ku", "zip": "108-8642", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Research Site", "city": "Morioka-shi", "zip": "020-8505", "country": "Japan", "geoPoint": {"lat": 39.7, "lon": 141.15}}, {"facility": "Research Site", "city": "Nagasaki-shi", "zip": "852-8501", "country": "Japan", "geoPoint": {"lat": 32.75, "lon": 129.88333}}, {"facility": "Research Site", "city": "Nagoya-shi", "zip": "467-0001", "country": "Japan", "geoPoint": {"lat": 35.18147, "lon": 136.90641}}, {"facility": "Research Site", "city": "Nishinomiya-shi", "zip": "663-8501", "country": "Japan", "geoPoint": {"lat": 34.71562, "lon": 135.33199}}, {"facility": "Research Site", "city": "Sagamihara-shi", "zip": "228-0815", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Research Site", "city": "Sakaide-shi", "zip": "762-8550", "country": "Japan"}, {"facility": "Research Site", "city": "Sapporo-shi", "zip": "064-0807", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Research Site", "city": "Sasebo-shi", "zip": "857-8511", "country": "Japan", "geoPoint": {"lat": 33.16832, "lon": 129.72501}}, {"facility": "Research Site", "city": "Seto-shi", "zip": "489-8642", "country": "Japan", "geoPoint": {"lat": 35.23333, "lon": 137.1}}, {"facility": "Research Site", "city": "Shibuya-ku", "zip": "150-0013", "country": "Japan", "geoPoint": {"lat": 35.469, "lon": 140.29807}}, {"facility": "Research Site", "city": "Shinagawa-ku", "zip": "142-8666", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Research Site", "city": "Shinjuku-ku", "zip": "162-8655", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "Research Site", "city": "Sumida-ku", "zip": "130-8587", "country": "Japan"}, {"facility": "Research Site", "city": "Takamatsu-shi", "zip": "760-0018", "country": "Japan", "geoPoint": {"lat": 34.33333, "lon": 134.05}}, {"facility": "Research Site", "city": "Toshima-ku", "zip": "171-0014", "country": "Japan"}, {"facility": "Research Site", "city": "Touon-shi", "zip": "791-0281", "country": "Japan"}, {"facility": "Research Site", "city": "Toyama-shi", "zip": "930-0859", "country": "Japan", "geoPoint": {"lat": 36.7, "lon": 137.21667}}, {"facility": "Research Site", "city": "Tsu-shi", "zip": "514-8507", "country": "Japan", "geoPoint": {"lat": 34.73333, "lon": 136.51667}}, {"facility": "Research Site", "city": "Tsukubo-gun", "zip": "701-0304", "country": "Japan"}, {"facility": "Research Site", "city": "Uozu-shi", "zip": "937-0042", "country": "Japan", "geoPoint": {"lat": 36.8, "lon": 137.4}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "227-8501", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "231-8682", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "232-0024", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "232-0066", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "236-0051", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Research Site", "city": "Guadalajara", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Mexico", "zip": "07760", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Research Site", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Research Site", "city": "Monterrey", "zip": "66465", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Research Site", "city": "Villahermosa", "zip": "86035", "country": "Mexico", "geoPoint": {"lat": 17.98689, "lon": -92.93028}}, {"facility": "Research Site", "city": "Caloocan City", "zip": "1400", "country": "Philippines", "geoPoint": {"lat": 14.65333, "lon": 120.98333}}, {"facility": "Research Site", "city": "Iloilo City", "zip": "5000", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Research Site", "city": "Lipa City", "country": "Philippines", "geoPoint": {"lat": 13.9411, "lon": 121.1631}}, {"facility": "Research Site", "city": "Pasig City", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.58691, "lon": 121.0614}}, {"facility": "Research Site", "city": "Quezon City", "zip": "1101", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Research Site", "city": "Quezon City", "zip": "1109", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Research Site", "city": "San Fernando", "zip": "2000", "country": "Philippines", "geoPoint": {"lat": 15.03425, "lon": 120.68445}}, {"facility": "Research Site", "city": "Chelyabinsk", "zip": "454021", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "Research Site", "city": "Ekaterinburg", "zip": "620039", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "Izhevsk", "zip": "426035", "country": "Russian Federation", "geoPoint": {"lat": 56.84976, "lon": 53.20448}}, {"facility": "Research Site", "city": "Moscow", "zip": "115682", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "127473", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Novosibirsk", "zip": "630008", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Novosibirsk", "zip": "630084", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Novosibirsk", "zip": "630117", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Research Site", "city": "Omsk", "zip": "644043", "country": "Russian Federation", "geoPoint": {"lat": 54.99244, "lon": 73.36859}}, {"facility": "Research Site", "city": "Perm", "zip": "614000", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "Research Site", "city": "Petrozavodsk", "zip": "185019", "country": "Russian Federation", "geoPoint": {"lat": 61.78491, "lon": 34.34691}}, {"facility": "Research Site", "city": "Pyatigorsk", "zip": "357538", "country": "Russian Federation", "geoPoint": {"lat": 44.04861, "lon": 43.05944}}, {"facility": "Research Site", "city": "Saint - Petersburg", "zip": "196211", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint Petersburg", "zip": "196601", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint-Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saratov", "zip": "410012", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Research Site", "city": "St. Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Ulyanovsk", "zip": "432009", "country": "Russian Federation", "geoPoint": {"lat": 54.32824, "lon": 48.38657}}, {"facility": "Research Site", "city": "Vladikavkaz", "zip": "362007", "country": "Russian Federation", "geoPoint": {"lat": 43.03667, "lon": 44.66778}}, {"facility": "Research Site", "city": "Volgograd", "zip": "400001", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Research Site", "city": "Yaroslavl", "zip": "150002", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Research Site", "city": "Boksburg North", "zip": "1460", "country": "South Africa", "geoPoint": {"lat": -26.20535, "lon": 28.25392}}, {"facility": "Research Site", "city": "Durban", "zip": "4092", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Mount Edgecombe", "zip": "4302", "country": "South Africa", "geoPoint": {"lat": -29.70667, "lon": 31.0251}}, {"facility": "Research Site", "city": "Mowbray", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.94802, "lon": 18.47333}}, {"facility": "Research Site", "city": "Port Elizabeth", "zip": "6001", "country": "South Africa", "geoPoint": {"lat": -33.91799, "lon": 25.57007}}, {"facility": "Research Site", "city": "Stanger", "zip": "4450", "country": "South Africa", "geoPoint": {"lat": -29.32816, "lon": 31.28954}}, {"facility": "Research Site", "city": "Kaohsiung Hsien", "zip": "TAIWAN", "country": "Taiwan"}, {"facility": "Research Site", "city": "Keelung", "country": "Taiwan", "geoPoint": {"lat": 25.12825, "lon": 121.7419}}, {"facility": "Research Site", "city": "New-Taipei", "zip": "22056", "country": "Taiwan", "geoPoint": {"lat": 25.01111, "lon": 121.44583}}, {"facility": "Research Site", "city": "Cherkasy", "zip": "18009", "country": "Ukraine", "geoPoint": {"lat": 49.42854, "lon": 32.06207}}, {"facility": "Research Site", "city": "Dnipropetrovsk", "zip": "49051", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Research Site", "city": "Ivano-Frankivsk", "zip": "76012", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Research Site", "city": "Kharkiv", "zip": "61035", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Research Site", "city": "Kharkiv", "zip": "61075", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Research Site", "city": "Kremenchuk", "zip": "39617", "country": "Ukraine", "geoPoint": {"lat": 49.06802, "lon": 33.42041}}, {"facility": "Research Site", "city": "Kyiv", "zip": "03049", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Lviv", "zip": "79010", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Research Site", "city": "Odesa", "zip": "65025", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Research Site", "city": "Sumy", "zip": "40000", "country": "Ukraine", "geoPoint": {"lat": 50.9216, "lon": 34.80029}}, {"facility": "Research Site", "city": "Sumy", "zip": "40022", "country": "Ukraine", "geoPoint": {"lat": 50.9216, "lon": 34.80029}}, {"facility": "Research Site", "city": "Uzhgorod", "zip": "88009", "country": "Ukraine", "geoPoint": {"lat": 48.61667, "lon": 22.3}}, {"facility": "Research Site", "city": "Zaporizhzhya", "zip": "69068", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Research Site", "city": "Zaporizhzhya", "zip": "69114", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Research Site", "city": "Bradford", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Research Site", "city": "Cambridge", "zip": "CB2 0QQ", "country": "United Kingdom", "geoPoint": {"lat": 52.2, "lon": 0.11667}}, {"facility": "Research Site", "city": "Chertsey", "zip": "KT16 0PZ", "country": "United Kingdom", "geoPoint": {"lat": 51.38812, "lon": -0.50782}}, {"facility": "Research Site", "city": "Glasgow", "zip": "G12 OYN", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Research Site", "city": "Leicester", "zip": "LE3 9QP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Research Site", "city": "Liverpool", "zip": "L7 8XP", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Research Site", "city": "Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Research Site", "city": "Northwood", "zip": "HA6 2RN", "country": "United Kingdom"}, {"facility": "Research Site", "city": "Sidcup", "zip": "DA14 6LT", "country": "United Kingdom", "geoPoint": {"lat": 51.42619, "lon": 0.1036}}, {"facility": "Research Site", "city": "Wishaw", "zip": "ML2 0DP", "country": "United Kingdom", "geoPoint": {"lat": 55.76667, "lon": -3.91667}}]}, "referencesModule": {"references": [{"pmid": "31315668", "type": "DERIVED", "citation": "Gottlow M, Svensson DJ, Lipkovich I, Huhn M, Bowen K, Wessman P, Colice G. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma. BMC Pulm Med. 2019 Jul 17;19(1):129. doi: 10.1186/s12890-019-0889-4."}, {"pmid": "30649752", "type": "DERIVED", "citation": "Carlsson M, Braddock M, Li Y, Wang J, Xu W, White N, Megally A, Hunter G, Colice G. Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma. Drug Saf. 2019 Jun;42(6):769-784. doi: 10.1007/s40264-018-00788-w."}, {"pmid": "29792288", "type": "DERIVED", "citation": "Panettieri RA Jr, Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E, Colice G, Brightling CE. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018 Jul;6(7):511-525. doi: 10.1016/S2213-2600(18)30184-X. Epub 2018 May 20."}, {"pmid": "29536781", "type": "DERIVED", "citation": "Panettieri RA Jr, Wang M, Braddock M, Bowen K, Colice G. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018 Mar 1;10(6):473-490. doi: 10.2217/imt-2017-0191. Epub 2018 Mar 14."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "This is commercially sensitive information."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "1696 patients signed informed consent, 1163 entered screening/run-in period, 856 patients were randomised to receive investigational product (IP) and 849 received treatment.\n\nThe primary population was the biomarker positive population, defined as all patients with baseline fractional exhaled nitric oxide (FeNO) \u226537 parts per billion (ppb).", "recruitmentDetails": "First patient enrolled: 30 Oct 2014; Last Patient Last Visit: 21 Sep 2017. Study performed at 242 sites in 13 countries.\n\nPatients were maintained on their currently prescribed inhaled corticosteroid long-acting \u03b22-agonist therapy and any additional maintenance asthma controller medications throughout the study period.", "groups": [{"id": "FG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) over a 52-week treatment period (up to 26 doses)."}, {"id": "FG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "periods": [{"title": "Randomised", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "428"}, {"groupId": "FG001", "numSubjects": "428"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "420"}, {"groupId": "FG001", "numSubjects": "417"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Did not receive treatment", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Without potential for 52 weeks of IP", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Duplicate patient", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "With Potential to Receive 52 Weeks of IP", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Includes all patients randomised with the potential to receive 52 weeks of IP and receiving any IP.", "numSubjects": "420"}, {"groupId": "FG001", "comment": "Includes all patients randomised with the potential to receive 52 weeks of IP and receiving any IP.", "numSubjects": "417"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "370"}, {"groupId": "FG001", "numSubjects": "365"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "52"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "16"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All patients in the full analysis set (FAS) with the potential to receive 52 weeks of IP and who received any IP (tralokinumab or placebo) were included in the baseline analysis.", "groups": [{"id": "BG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "BG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "420"}, {"groupId": "BG001", "value": "417"}, {"groupId": "BG002", "value": "837"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.3", "spread": "15.6"}, {"groupId": "BG001", "value": "48.0", "spread": "15.5"}, {"groupId": "BG002", "value": "47.6", "spread": "15.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "276"}, {"groupId": "BG001", "value": "290"}, {"groupId": "BG002", "value": "566"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "144"}, {"groupId": "BG001", "value": "127"}, {"groupId": "BG002", "value": "271"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "83"}, {"groupId": "BG001", "value": "88"}, {"groupId": "BG002", "value": "171"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "51"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "283"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "564"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "45"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Annualised Asthma Exacerbation Rate (AAER) up to Week 52", "description": "Asthma exacerbation was defined as a worsening of asthma that led to any of the following:\n\n* Use of systemic corticosteroids for at least 3 days; a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of systemic corticosteroids.\n* An emergency room (ER) or urgent care (UC) visit (defined as evaluation and treatment for \\<24 hours in an ER or UC centre) due to asthma that required systemic corticosteroids (see above).\n* An inpatient hospitalisation (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for \u226524 hours) due to asthma.\n\nAAER = number of exacerbations\\*365.25 / (follow-up date - date of randomisation + 1) (where maximum follow-up time for a patient was approximately 52 weeks).\n\nAAER in the tralokinumab group was compared to that seen in the placebo group up to Week 52 using a negative binomial model; rate ratios and rate reductions are both presented for comparative statistical analyses.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/year", "timeFrame": "Baseline (Week 0) up to Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "308"}, {"groupId": "OG003", "value": "290"}, {"groupId": "OG004", "value": "420"}, {"groupId": "OG005", "value": "417"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.80", "lowerLimit": "0.57", "upperLimit": "1.11"}, {"groupId": "OG001", "value": "0.95", "lowerLimit": "0.68", "upperLimit": "1.31"}, {"groupId": "OG002", "value": "0.87", "lowerLimit": "0.71", "upperLimit": "1.06"}, {"groupId": "OG003", "value": "0.77", "lowerLimit": "0.63", "upperLimit": "0.95"}, {"groupId": "OG004", "value": "0.84", "lowerLimit": "0.71", "upperLimit": "1.00"}, {"groupId": "OG005", "value": "0.82", "lowerLimit": "0.69", "upperLimit": "0.97"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of AAER (rate ratio): Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nA variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The null hypothesis was that the exacerbation rate during the 52-week double-blind treatment period on tralokinumab was equal to the corresponding exacerbation rate on placebo.", "pValue": "0.4656", "statisticalMethod": "Negative binomial", "paramType": "Rate ratio", "paramValue": "0.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.53", "ciUpperLimit": "1.34", "estimateComment": "Covariates in the model included treatment group, geographical region, age group, periostin group at baseline and number of exacerbations in the year before the study."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of AAER (rate ratio): Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nA variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The null hypothesis was that the exacerbation rate during the 52-week double-blind treatment period on tralokinumab was equal to the corresponding exacerbation rate on placebo.", "pValue": "0.4126", "statisticalMethod": "Negative binomial", "paramType": "Rate ratio", "paramValue": "1.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.85", "ciUpperLimit": "1.50", "estimateComment": "Covariates in the model included treatment group, geographical region, age group, periostin group at baseline and number of exacerbations in the year before the study."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of AAER (rate reduction): Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nA variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The null hypothesis was that the exacerbation rate during the 52-week double-blind treatment period on tralokinumab was equal to the corresponding exacerbation rate on placebo.", "pValue": "0.4656", "statisticalMethod": "Negative binominal", "paramType": "Rate reduction", "paramValue": "15.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.71", "ciUpperLimit": "47.01", "estimateComment": "Covariates in the model included treatment group, geographical region, age group, periostin group at baseline and number of exacerbations in the year before the study."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of AAER (rate ratio): FAS population; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The null hypothesis was that the exacerbation rate during the 52-week double-blind treatment period on tralokinumab was equal to the corresponding exacerbation rate on placebo.", "pValue": "0.8027", "statisticalMethod": "Negative binomial", "paramType": "Rate ratio", "paramValue": "1.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.81", "ciUpperLimit": "1.31", "estimateComment": "Covariates in the model included treatment group, geographical region, age group, periostin group at baseline and number of exacerbations in the year before the study."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of AAER (rate reduction): FAS population; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The null hypothesis was that the exacerbation rate during the 52-week double-blind treatment period on tralokinumab was equal to the corresponding exacerbation rate on placebo.", "pValue": "0.8027", "statisticalMethod": "Negative binominal", "paramType": "Rate reduction", "paramValue": "-3.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-31.46", "ciUpperLimit": "19.08", "estimateComment": "Covariates in the model included treatment group, geographical region, age group, periostin group at baseline and number of exacerbations in the year before the study."}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline to Week 52 in Pre-dose/Pre-bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV1)", "description": "Lung function was assessed by FEV1 which was measured by spirometry. Spirometry was performed by the Investigator or authorised delegate according to American Thoracic Society/European Respiratory Society guidelines. The mean percent change from baseline in pre-BD FEV1 at Week 52 is presented.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change from baseline", "timeFrame": "Baseline (Week 0) and Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "282"}, {"groupId": "OG003", "value": "250"}, {"groupId": "OG004", "value": "384"}, {"groupId": "OG005", "value": "358"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.769", "spread": "29.628"}, {"groupId": "OG001", "value": "16.632", "spread": "31.906"}, {"groupId": "OG002", "value": "13.103", "spread": "24.641"}, {"groupId": "OG003", "value": "8.395", "spread": "21.962"}, {"groupId": "OG004", "value": "14.546", "spread": "26.065"}, {"groupId": "OG005", "value": "10.528", "spread": "25.475"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of % change from baseline in pre-dose/pre-BD FEV1 at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nRestricted maximum likelihood (REML) based repeated measures analysis on patients with a baseline pre-dose/pre-BD FEV1 assessment.\n\nA variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6033", "statisticalMethod": "Repeated measures analysis", "paramType": "Least square (LS) Mean difference", "paramValue": "1.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.16", "ciUpperLimit": "8.88", "estimateComment": "Fixed categorical effects of treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of % change from baseline in pre-dose/pre-BD FEV1 at Week 52: Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis on patients with a baseline pre-dose/pre-BD FEV1 assessment.\n\nA variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1276", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "3.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.97", "ciUpperLimit": "7.70", "estimateComment": "Fixed categorical effects of treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of % change from baseline in pre-dose/pre-BD FEV1 at Week 52: FAS population; Tralo 300 mg Q2W vs placebo. REML based repeated measures analysis on patients with a baseline pre-dose/pre-BD FEV1 assessment", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1164", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "2.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.73", "ciUpperLimit": "6.62", "estimateComment": "Fixed categorical effects of treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Total Asthma Symptom Score (Bi-weekly Means)", "description": "Asthma symptoms during night-time and daytime were recorded by the patient each morning and evening in the Asthma Daily Diary. Symptoms were recorded using a 4-point response scale, which ranged from 0 to 3, where 0 indicated no asthma symptoms. Asthma symptom daytime score (recorded in the evening), night-time score (recorded in the morning), and total score were calculated separately. The daily asthma symptom total score was calculated by taking the sum of the night-time and daytime asthma symptom scores recorded each day, ranging from 0 to 6. A lower symptom score indicated a better outcome. The change from baseline in bi-weekly mean daily asthma symptom total score is presented.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline (Week 0) and Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "215"}, {"groupId": "OG003", "value": "223"}, {"groupId": "OG004", "value": "297"}, {"groupId": "OG005", "value": "309"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.18", "spread": "0.98"}, {"groupId": "OG001", "value": "-1.06", "spread": "1.25"}, {"groupId": "OG002", "value": "-0.98", "spread": "1.04"}, {"groupId": "OG003", "value": "-1.02", "spread": "1.24"}, {"groupId": "OG004", "value": "-1.04", "spread": "1.04"}, {"groupId": "OG005", "value": "-1.02", "spread": "1.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of mean change from baseline in total asthma symptom score at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1456", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-0.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.47", "ciUpperLimit": "0.07", "estimateComment": "Fixed categorical effects of baseline asthma symptom score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of mean change from baseline in total asthma symptom score at Week 52: Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6548", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.13", "ciUpperLimit": "0.20", "estimateComment": "Fixed categorical effects of baseline asthma symptom score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of mean change from baseline in total asthma symptom score at Week 52: FAS population; Tralo 300 mg Q2W vs placebo. REML based repeated measures analysis.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5763", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.18", "ciUpperLimit": "0.10", "estimateComment": "Fixed categorical effects of baseline asthma symptom score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score", "description": "The AQLQ(S)+12 is a questionnaire that measures health-related quality of life for patients with asthma aged 12 and older. The questionnaire comprises 32 questions and has 4 separate domains (asthma symptoms, activity limitations, emotional function and environmental stimuli). Patients were asked to recall their experiences during the previous 2 weeks and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The total score was calculated as the mean response to all questions, ranging from 1 (severe impairment) to 7 (no impairment). Individual AQLQ(S)+12 total score changes of \u22650.5 were considered to be clinically meaningful. The mean change from baseline in AQLQ(S)+12 score at Week 52 is presented.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline (Week 0) and Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "77"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "242"}, {"groupId": "OG003", "value": "230"}, {"groupId": "OG004", "value": "321"}, {"groupId": "OG005", "value": "318"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.35", "spread": "1.06"}, {"groupId": "OG001", "value": "1.20", "spread": "1.22"}, {"groupId": "OG002", "value": "1.13", "spread": "1.07"}, {"groupId": "OG003", "value": "1.23", "spread": "1.25"}, {"groupId": "OG004", "value": "1.18", "spread": "1.07"}, {"groupId": "OG005", "value": "1.21", "spread": "1.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change in mean score from baseline for AQLQ(S)+12 at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0874", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.04", "ciUpperLimit": "0.57", "estimateComment": "Fixed categorical effects of baseline AQLQ(S)+12 score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of change in mean score from baseline for AQLQ(S)+12 at Week 52: Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9083", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.20", "ciUpperLimit": "0.17", "estimateComment": "Fixed categorical effects of baseline AQLQ(S)+12 score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of change in mean score from baseline for AQLQ(S)+12 at Week 52: FAS population; Tralo 300 mg Q2W vs placebo. REML based repeated measures analysis.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4506", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.10", "ciUpperLimit": "0.22", "estimateComment": "Fixed categorical effects of baseline AQLQ(S)+12 score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Asthma Control Questionnaire-6 (ACQ-6) Score", "description": "The ACQ-6 questionnaire is a shortened version of the ACQ (omitting FEV1 measurement) that assesses asthma symptoms (night-time awakenings, symptoms on waking, activity limitation, dyspnoea, wheezing) and rescue short-acting \u03b22-agonists medication use during the past week. Questions were weighted equally and scored on a 7-point scale from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score was the mean of the responses, ranging from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of \u22640.75 indicate well-controlled asthma, scores between 0.75 and \u22641.5 indicate partly controlled asthma and a score \\>1.5 indicates not well-controlled asthma. Individual changes of at least 0.5 were considered to be clinically meaningful. The mean change from baseline in ACQ-6 score at Week 52 is presented.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline (Week 0) and Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "86"}, {"groupId": "OG002", "value": "254"}, {"groupId": "OG003", "value": "243"}, {"groupId": "OG004", "value": "341"}, {"groupId": "OG005", "value": "334"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.26", "spread": "1.01"}, {"groupId": "OG001", "value": "-1.14", "spread": "1.12"}, {"groupId": "OG002", "value": "-1.07", "spread": "1.02"}, {"groupId": "OG003", "value": "-1.11", "spread": "1.13"}, {"groupId": "OG004", "value": "-1.12", "spread": "1.02"}, {"groupId": "OG005", "value": "-1.11", "spread": "1.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of change in mean score from baseline for ACQ-6 at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0400", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.53", "ciUpperLimit": "-0.01", "estimateComment": "Fixed categorical effects of baseline ACQ-6 score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of change in mean score from baseline for ACQ-6 at Week 52: Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9735", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.16", "ciUpperLimit": "0.16", "estimateComment": "Fixed categorical effects of baseline ACQ-6 score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of change in mean score from baseline for ACQ-6 at Week 52: FAS population; Tralo 300 mg Q2W vs placebo. REML based repeated measures analysis.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2432", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.21", "ciUpperLimit": "0.05", "estimateComment": "Fixed categorical effects of baseline ACQ-6 score, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}]}, {"type": "SECONDARY", "title": "AAER Associated With an ER/UC Visit, or a Hospitalisation up to Week 52", "description": "The annual rate of exacerbations associated with an ER/UC visit or hospitalisation up to Week 52 are presented for non-adjudicated data (i.e. events assessed by the Investigator and recorded in the electronic case report form).\n\nAAER = number of exacerbations\\*365.25 / (follow-up date - date of randomisation + 1) (where maximum follow-up time for a patient was approximately 52 weeks).", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/year", "timeFrame": "Baseline (Week 0) up to Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "308"}, {"groupId": "OG003", "value": "290"}, {"groupId": "OG004", "value": "420"}, {"groupId": "OG005", "value": "417"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "0.03", "upperLimit": "0.14"}, {"groupId": "OG001", "value": "0.16", "lowerLimit": "0.09", "upperLimit": "0.29"}, {"groupId": "OG002", "value": "0.09", "lowerLimit": "0.06", "upperLimit": "0.14"}, {"groupId": "OG003", "value": "0.11", "lowerLimit": "0.07", "upperLimit": "0.17"}, {"groupId": "OG004", "value": "0.08", "lowerLimit": "0.06", "upperLimit": "0.12"}, {"groupId": "OG005", "value": "0.12", "lowerLimit": "0.09", "upperLimit": "0.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of AAER associated with an ER/UC visit or hospitalisation: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nA variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0576", "statisticalMethod": "Negative binomial", "paramType": "Rate ratio", "paramValue": "0.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.15", "ciUpperLimit": "1.03", "estimateComment": "Covariates in the model included treatment group, geographical region, age group, periostin group at baseline and number of exacerbations resulting in hospitalisation or ER treatment (yes/no) in the year before the study."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of AAER associated with an ER/UC visit or hospitalisation: Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nA variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5249", "statisticalMethod": "Negative binomial", "paramType": "Rate ratio", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.46", "ciUpperLimit": "1.48", "estimateComment": "Covariates in the model included treatment group, geographical region, age group, periostin group at baseline and number of exacerbations resulting in hospitalisation or ER treatment (yes/no) in the year before the study."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of AAER associated with an ER/UC visit or hospitalisation: FAS population; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1155", "statisticalMethod": "Negative binomial", "paramType": "Rate ratio", "paramValue": "0.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.41", "ciUpperLimit": "1.10", "estimateComment": "Covariates in the model included treatment group, geographical region, age group, periostin group at baseline and number of exacerbations resulting in hospitalisation or ER treatment (yes/no) in the year before the study."}]}, {"type": "SECONDARY", "title": "Change From Baseline in European Quality of Life - 5 Dimension 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Scores at Week 52", "description": "The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The patient was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. The questionnaire also included a VAS, where the patient was asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state. The mean change from baseline in EQ-5D-5L VAS scores at Week 52 is presented.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline (Week 0) and Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "85"}, {"groupId": "OG002", "value": "233"}, {"groupId": "OG003", "value": "224"}, {"groupId": "OG004", "value": "317"}, {"groupId": "OG005", "value": "313"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.58", "spread": "15.21"}, {"groupId": "OG001", "value": "11.58", "spread": "17.26"}, {"groupId": "OG002", "value": "11.67", "spread": "17.18"}, {"groupId": "OG003", "value": "12.01", "spread": "17.43"}, {"groupId": "OG004", "value": "12.46", "spread": "16.67"}, {"groupId": "OG005", "value": "11.66", "spread": "17.41"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Asthma Rescue Medication Use at Week 52 (Bi-weekly Means)", "description": "Salbutamol, albuterol or levalbuterol were used as rescue medication during the study in the event of a worsening of asthma symptoms. Rescue medication use was measured by the bi-weekly mean number of inhalations (puffs) per day, calculated as: total morning puffs + total evening puffs + 2\\*(total morning nebuliser use + total evening nebuliser use)/ total number of days with data in bi-weekly period. The change from baseline in bi-weekly mean total asthma rescue medication use at Week 52 is presented.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs/day", "timeFrame": "Baseline (Week 0) and Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "215"}, {"groupId": "OG003", "value": "223"}, {"groupId": "OG004", "value": "297"}, {"groupId": "OG005", "value": "309"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.86", "spread": "3.26"}, {"groupId": "OG001", "value": "-1.73", "spread": "4.59"}, {"groupId": "OG002", "value": "-2.01", "spread": "2.93"}, {"groupId": "OG003", "value": "-2.08", "spread": "4.28"}, {"groupId": "OG004", "value": "-2.25", "spread": "3.03"}, {"groupId": "OG005", "value": "-1.97", "spread": "4.34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of mean change from baseline in rescue medication use at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0360", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-0.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.85", "ciUpperLimit": "-0.06", "estimateComment": "Fixed categorical effects of baseline rescue medication use, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of mean change from baseline in rescue medication use at Week 52: Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5864", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.40", "ciUpperLimit": "0.70", "estimateComment": "Fixed categorical effects of baseline rescue medication use, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of mean change from baseline in rescue medication use at Week 52: FAS population; Tralo 300 mg Q2W vs placebo. REML based repeated measures analysis.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4689", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "0.29", "estimateComment": "Fixed categorical effects of baseline rescue medication use, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Home Peak Expiratory Flow (PEF) (Morning and Evening) at Week 52", "description": "Home PEF testing was performed by the patient using an electronic, hand-held spirometer (peak flow meter) and was performed in the morning upon awakening (prior to taking their morning asthma controller) and in the evening at bedtime (prior to taking their evening asthma controller). The mean change from baseline in home PEF values at Week 52 are presented separately for morning and evening.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Baseline (Week 0) and Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "86"}, {"groupId": "OG002", "value": "233"}, {"groupId": "OG003", "value": "222"}, {"groupId": "OG004", "value": "322"}, {"groupId": "OG005", "value": "313"}]}], "classes": [{"title": "Morning PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "81"}, {"groupId": "OG002", "value": "231"}, {"groupId": "OG003", "value": "222"}, {"groupId": "OG004", "value": "318"}, {"groupId": "OG005", "value": "308"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.35", "spread": "74.00"}, {"groupId": "OG001", "value": "18.80", "spread": "86.24"}, {"groupId": "OG002", "value": "6.72", "spread": "73.82"}, {"groupId": "OG003", "value": "6.10", "spread": "72.28"}, {"groupId": "OG004", "value": "10.66", "spread": "73.88"}, {"groupId": "OG005", "value": "9.43", "spread": "76.01"}]}]}, {"title": "Evening PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "86"}, {"groupId": "OG002", "value": "233"}, {"groupId": "OG003", "value": "222"}, {"groupId": "OG004", "value": "322"}, {"groupId": "OG005", "value": "313"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.15", "spread": "69.20"}, {"groupId": "OG001", "value": "8.88", "spread": "79.72"}, {"groupId": "OG002", "value": "1.72", "spread": "79.58"}, {"groupId": "OG003", "value": "0.17", "spread": "73.66"}, {"groupId": "OG004", "value": "5.72", "spread": "77.01"}, {"groupId": "OG005", "value": "2.91", "spread": "74.94"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of mean change from baseline in morning PEF at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5094", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "6.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.13", "ciUpperLimit": "24.43", "estimateComment": "Fixed categorical effects of baseline PEF (morning), treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of mean change from baseline in morning PEF at Week 52: Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5984", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "3.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.22", "ciUpperLimit": "14.26", "estimateComment": "Fixed categorical effects of baseline PEF (morning), treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of mean change from baseline in evening PEF at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3971", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "7.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.32", "ciUpperLimit": "26.00", "estimateComment": "Model included fixed categorical effects of baseline PEF (evening), treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as fixed covariate."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of mean change from baseline in evening PEF at Week 52: Biomarker negative population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5310", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "3.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.65", "ciUpperLimit": "14.83", "estimateComment": "Model included fixed categorical effects of baseline PEF (evening), treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as fixed covariate."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of mean change from baseline in morning PEF at Week 52: FAS population; Tralo 300 mg Q2W vs placebo. REML based repeated measures analysis.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4764", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "3.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.06", "ciUpperLimit": "12.97", "estimateComment": "Model included fixed categorical effects of baseline PEF (morning), treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as fixed covariate."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of mean change from baseline in evening PEF at Week 52: FAS population; Tralo 300 mg Q2W vs placebo. REML based repeated measures analysis.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4221", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "3.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.60", "ciUpperLimit": "13.37", "estimateComment": "Model included fixed categorical effects of baseline PEF (evening), treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as fixed covariate."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Night-time Awakenings Due to Asthma Requiring Rescue Medication Use at Week 52 (Bi-weekly Means [Percentage])", "description": "The patient captured night-time awakenings (yes/no) and the use of rescue medication during these awakenings (yes/no) each morning in the Asthma Daily Diary. Night-time awakenings (percentage) was defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data. The change from baseline in bi-weekly means (percentage) night-time awakenings due to asthma requiring rescue medication use at Week 52 is presented.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of nights with awakenings", "timeFrame": "Baseline (Week 0) and Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "270"}, {"groupId": "OG003", "value": "247"}, {"groupId": "OG004", "value": "368"}, {"groupId": "OG005", "value": "348"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-37.86", "spread": "38.36"}, {"groupId": "OG001", "value": "-34.06", "spread": "34.96"}, {"groupId": "OG002", "value": "-34.65", "spread": "34.34"}, {"groupId": "OG003", "value": "-35.67", "spread": "37.37"}, {"groupId": "OG004", "value": "-35.60", "spread": "35.40"}, {"groupId": "OG005", "value": "-35.05", "spread": "36.63"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of mean change from baseline in number (%) of awakenings at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1099", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-5.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.21", "ciUpperLimit": "1.14", "estimateComment": "Fixed categorical effects of baseline number (%) of awakenings, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of mean change from baseline in number (%) of awakenings at Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.\n\nREML based repeated measures analysis. A variable for the biomarker population (positive, negative) as well as a treatment-by-biomarker population interaction term and a 3-way biomarker population-by-treatment-by-visit interaction term was included in the analysis model.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8112", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.33", "ciUpperLimit": "4.25", "estimateComment": "Fixed categorical effects of baseline number (%) of awakenings, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of mean change from baseline in number (%) of awakenings at Week 52: FAS population; Tralo 300 mg Q2W vs placebo. REML based repeated measures analysis.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4645", "statisticalMethod": "Repeated measures analysis", "paramType": "LS Mean difference", "paramValue": "-1.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.40", "ciUpperLimit": "2.01", "estimateComment": "Fixed categorical effects of baseline number (%) of awakenings, treatment group, geographical region, age group, periostin group, visit and treatment-by-visit interaction and number of asthma exacerbations in year before study as a fixed covariate."}]}, {"type": "SECONDARY", "title": "Number of Patients With \u22651 Asthma Exacerbation up to Week 52", "description": "The number of patients with \u22651 asthma exacerbation up to Week 52 is presented.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0) up to Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "308"}, {"groupId": "OG003", "value": "290"}, {"groupId": "OG004", "value": "420"}, {"groupId": "OG005", "value": "417"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "125"}, {"groupId": "OG003", "value": "117"}, {"groupId": "OG004", "value": "163"}, {"groupId": "OG005", "value": "171"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Comparison of number of patients with \u2265 1 asthma exacerbations up to Week 52: Biomarker positive population; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3440", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "0.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.44", "ciUpperLimit": "1.33", "estimateComment": "The estimate of each odds ratio was obtained from a Cochran-Mantel-Haenszel test controlling for geographical region, age group and periostin group at baseline."}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Comparison of number of patients with \u2265 1 asthma exacerbations up to Week 52: Biomarker negative population; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7768", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "1.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.75", "ciUpperLimit": "1.46", "estimateComment": "The estimate of each odds ratio was obtained from a Cochran-Mantel-Haenszel test controlling for geographical region, age group and periostin group at baseline."}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Comparison of number of patients with \u2265 1 asthma exacerbations up to Week 52: FAS population; Tralo 300 mg Q2W vs placebo.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5276", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "0.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.69", "ciUpperLimit": "1.21", "estimateComment": "The estimate of each odds ratio was obtained from a Cochran-Mantel-Haenszel test controlling for geographical region, age group and periostin group at baseline."}]}, {"type": "SECONDARY", "title": "Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questions (WPAI+CIQ): Productivity Loss at Week 52", "description": "The WPAI+CIQ consists of questions about how asthma and asthma-related issues impact a patient's ability to work, attend classes and perform regular daily activities. The questionnaire contains 10 questions relating to the patient's experience over the previous 7 days.\n\nThe WPAI+CIQ outcomes for productivity loss are presented separately for those currently employed and for those currently in school and are expressed as mean productivity loss (percentage) at Week 52, with higher numbers indicating less productivity.\n\nWork Productivity Loss = {Q2/(Q2+Q4)+\\[(1-Q2/(Q2+Q4))x(Q5/10)\\]}\\*100 (Absenteeism = Q2/(Q2+Q4)\\*100; Presenteeism = (Q5/10)\\*100).\n\nClass Productivity Loss = {Q7/(Q7+Q8) + \\[(1-Q7/(Q7+Q8))x(Q9/10)\\]}\\*100 (Absenteeism = Q7/(Q7+Q8)\\*100; Presenteeism = (Q9/10)\\*100).\n\nNote: QX refers to response to question number X on WPAI+CIQ questionnaire.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent productivity loss", "timeFrame": "At Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "46"}, {"groupId": "OG002", "value": "105"}, {"groupId": "OG003", "value": "104"}, {"groupId": "OG004", "value": "154"}, {"groupId": "OG005", "value": "151"}]}], "classes": [{"title": "Productivity loss - currently employed", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "92"}, {"groupId": "OG003", "value": "90"}, {"groupId": "OG004", "value": "137"}, {"groupId": "OG005", "value": "125"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.51", "spread": "24.47"}, {"groupId": "OG001", "value": "28.15", "spread": "27.39"}, {"groupId": "OG002", "value": "23.36", "spread": "23.39"}, {"groupId": "OG003", "value": "31.05", "spread": "27.20"}, {"groupId": "OG004", "value": "23.43", "spread": "23.66"}, {"groupId": "OG005", "value": "30.17", "spread": "27.08"}]}]}, {"title": "Productivity loss - currently in school", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "14"}, {"groupId": "OG004", "value": "17"}, {"groupId": "OG005", "value": "26"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "28.89", "spread": "34.21"}, {"groupId": "OG001", "value": "37.92", "spread": "28.72"}, {"groupId": "OG002", "value": "25.99", "spread": "32.17"}, {"groupId": "OG003", "value": "19.67", "spread": "29.06"}, {"groupId": "OG004", "value": "28.03", "spread": "31.01"}, {"groupId": "OG005", "value": "28.09", "spread": "29.80"}]}]}]}, {"type": "SECONDARY", "title": "WPAI+CIQ: Activity Impairment at Week 52", "description": "The WPAI+CIQ consists of questions about how asthma and asthma-related issues impact a patient's ability to work, attend classes and perform regular daily activities. The questionnaire contains 10 questions relating to the patient's experience over the previous 7 days.\n\nThe WPAI+CIQ outcomes for activity impairment are presented separately for those currently employed and for those currently in school and are expressed as mean impairment percentages at Week 52, with higher numbers indicating greater impairment.\n\nActivity impairment = (Q10/10)\\*100. Note: QX refers to response to question number X on WPAI+CIQ questionnaire.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study. Only patients with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent impairment", "timeFrame": "At Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "116"}, {"groupId": "OG003", "value": "110"}, {"groupId": "OG004", "value": "169"}, {"groupId": "OG005", "value": "160"}]}], "classes": [{"title": "Activity Impairment - currently employed", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "100"}, {"groupId": "OG003", "value": "94"}, {"groupId": "OG004", "value": "147"}, {"groupId": "OG005", "value": "131"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.89", "spread": "18.81"}, {"groupId": "OG001", "value": "25.28", "spread": "28.63"}, {"groupId": "OG002", "value": "20.50", "spread": "20.42"}, {"groupId": "OG003", "value": "26.49", "spread": "23.59"}, {"groupId": "OG004", "value": "20.68", "spread": "19.82"}, {"groupId": "OG005", "value": "26.11", "spread": "24.89"}]}]}, {"title": "Activity Impairment - currently in school", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}, {"groupId": "OG004", "value": "22"}, {"groupId": "OG005", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.00", "spread": "18.71"}, {"groupId": "OG001", "value": "33.85", "spread": "26.63"}, {"groupId": "OG002", "value": "26.88", "spread": "30.49"}, {"groupId": "OG003", "value": "23.13", "spread": "30.27"}, {"groupId": "OG004", "value": "24.55", "spread": "27.38"}, {"groupId": "OG005", "value": "27.93", "spread": "28.71"}]}]}]}, {"type": "SECONDARY", "title": "Asthma-related Healthcare Encounters by Type up to Week 52", "description": "Broad-based healthcare utilisation asthma-related event information was collected by the Investigator/authorised delegate at each visit. At Visit 1, healthcare resource utilisation information was collected with a 1-year recall period; subsequent visits collected information with a recall period of 'since the last scheduled visit'. Total number of times the healthcare encounter occurred was calculated across all patients for each of the following categories:\n\n* Ambulance transport,\n* Emergency room visits,\n* Unscheduled outpatient visits (visit to specialist and/or visit to primary healthcare physician and/or other healthcare visit),\n* Home visits (home visit, physician and/or other healthcare professional),\n* Telephone calls (telephone calls to physician and/or nurse), and\n* Advanced pulmonary function test.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Encounters", "timeFrame": "Baseline (Week 0) up to Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "308"}, {"groupId": "OG003", "value": "290"}, {"groupId": "OG004", "value": "420"}, {"groupId": "OG005", "value": "417"}]}], "classes": [{"title": "Ambulance transport", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "20"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "41"}]}]}, {"title": "Emergency room visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "65"}, {"groupId": "OG003", "value": "70"}, {"groupId": "OG004", "value": "87"}, {"groupId": "OG005", "value": "99"}]}]}, {"title": "Unscheduled outpatient visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "513"}, {"groupId": "OG001", "value": "579"}, {"groupId": "OG002", "value": "1274"}, {"groupId": "OG003", "value": "1216"}, {"groupId": "OG004", "value": "1798"}, {"groupId": "OG005", "value": "1834"}]}]}, {"title": "Home visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "26"}, {"groupId": "OG004", "value": "59"}, {"groupId": "OG005", "value": "44"}]}]}, {"title": "Telephone calls", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "76"}, {"groupId": "OG002", "value": "112"}, {"groupId": "OG003", "value": "117"}, {"groupId": "OG004", "value": "163"}, {"groupId": "OG005", "value": "196"}]}]}, {"title": "Advanced pulmonary function test", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "26"}, {"groupId": "OG004", "value": "51"}, {"groupId": "OG005", "value": "46"}]}]}]}, {"type": "SECONDARY", "title": "Asthma-related Healthcare Encounters by Type up to Week 52: Hospitalisations", "description": "Broad-based healthcare utilisation asthma-related event information was collected by the Investigator/authorised delegate at each visit. At Visit 1, healthcare resource utilisation information was collected with a 1-year recall period; subsequent visits collected information with a recall period of 'since the last scheduled visit'. Total number of days spent in hospital was calculated across all patients for the following healthcare encounter category:\n\n\u2022 Hospitalisations (hospitalisations, intensive care and/or general care).", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Days", "timeFrame": "Baseline (Week 0) up to Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "308"}, {"groupId": "OG003", "value": "290"}, {"groupId": "OG004", "value": "420"}, {"groupId": "OG005", "value": "417"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "82"}, {"groupId": "OG001", "value": "175"}, {"groupId": "OG002", "value": "334"}, {"groupId": "OG003", "value": "414"}, {"groupId": "OG004", "value": "417"}, {"groupId": "OG005", "value": "590"}]}]}]}, {"type": "SECONDARY", "title": "Asthma-related Healthcare Encounters by Type up to Week 52: Spirometry", "description": "Broad-based healthcare utilisation asthma-related event information was collected by the Investigator/authorised delegate at each visit. At Visit 1, healthcare resource utilisation information was collected with a 1-year recall period; subsequent visits collected information with a recall period of 'since the last scheduled visit'. Total number of assessments was calculated across all patients for the following healthcare encounter category:\n\n\u2022 Spirometry.", "populationDescription": "The FAS included all randomised patients with the potential to receive 52 weeks of IP and receiving any IP, irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Assessments", "timeFrame": "Baseline (Week 0) up to Week 52", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Positive - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG002", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG003", "title": "Biomarker Negative - Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG004", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG005", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "308"}, {"groupId": "OG003", "value": "290"}, {"groupId": "OG004", "value": "420"}, {"groupId": "OG005", "value": "417"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "284"}, {"groupId": "OG003", "value": "270"}, {"groupId": "OG004", "value": "434"}, {"groupId": "OG005", "value": "426"}]}]}]}, {"type": "SECONDARY", "title": "Serum Trough Concentration (Ctrough) of Tralokinumab During the Treatment Period up to Week 72", "description": "To evaluate the pharmacokinetics (PK), pre-dose blood samples were collected at each visit and tralokinumab concentrations in serum were determined. Mean Ctrough concentrations are presented at each indicated visit up to Week 72.", "populationDescription": "All patients in the FAS who received tralokinumab and who had PK blood samples were included in the PK analysis set. Only patients in the biomarker positive and negative PK populations and with data available at the timepoints of testing were included in the analyses.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "micrograms/millilitre", "timeFrame": "Blood samples were collected pre-dose at Baseline (Week 0), and at Week 2, Week 8, Week 26, Week 56 (follow-up) and Week 72 (follow-up)", "groups": [{"id": "OG000", "title": "Biomarker Positive - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker positive population (primary population) had baseline FeNO \u226537 ppb."}, {"id": "OG001", "title": "Biomarker Negative - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). Patients in the biomarker negative population (complement population) had baseline FeNO \\<37 ppb."}, {"id": "OG002", "title": "Total - Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses). 'Total' treatment arm represents all patients receiving tralokinumab in both the biomarker positive and biomarker negative patient populations."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "302"}, {"groupId": "OG002", "value": "410"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "302"}, {"groupId": "OG002", "value": "410"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Value was not calculable since below level of detection."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Value was not calculable since below level of detection."}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "Value was not calculable since below level of detection."}]}]}, {"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "293"}, {"groupId": "OG002", "value": "396"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "24.049", "spread": "172.475"}, {"groupId": "OG001", "value": "20.916", "spread": "280.452"}, {"groupId": "OG002", "value": "21.690", "spread": "248.876"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "280"}, {"groupId": "OG002", "value": "385"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "55.887", "spread": "206.478"}, {"groupId": "OG001", "value": "52.324", "spread": "226.298"}, {"groupId": "OG002", "value": "53.272", "spread": "220.301"}]}]}, {"title": "Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "274"}, {"groupId": "OG002", "value": "373"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "58.375", "spread": "145.256"}, {"groupId": "OG001", "value": "47.707", "spread": "319.456"}, {"groupId": "OG002", "value": "50.332", "spread": "264.686"}]}]}, {"title": "Week 56 (follow-up)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "275"}, {"groupId": "OG002", "value": "371"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.363", "spread": "591.282"}, {"groupId": "OG001", "value": "12.513", "spread": "707.267"}, {"groupId": "OG002", "value": "12.474", "spread": "671.922"}]}]}, {"title": "Week 72 (follow-up)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "264"}, {"groupId": "OG002", "value": "356"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.325", "spread": "251.436"}, {"groupId": "OG001", "value": "0.384", "spread": "242.035"}, {"groupId": "OG002", "value": "0.368", "spread": "244.398"}]}]}]}, {"type": "SECONDARY", "title": "Incidence Rate of Positive Anti-drug Antibodies (ADAs) Including the Characterization of Their Neutralizing Potential", "description": "Assessments of ADA were performed using a tiered approach (screening, confirmatory and titering assays). Confirmed ADA positive samples were also tested for the presence of neutralising antibodies (nAb). ADA prevalence was defined as proportion of the study population having drug-reactive antibodies at any point in time. ADA incidence (treatment-emergent ADA) was defined as the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA. Persistently positive was defined as positive at \u22652 post-baseline assessments (with \u226516 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher level following drug administration. Note: 'positive' is denoted by 'pos' in some category titles.", "populationDescription": "The ADA evaluable population included all patients in the safety analysis set (i.e. those who had received any IP) who had non-missing baseline ADA and at least 1 non-missing post-baseline ADA result.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline (Week 0), Week 26, Week 56 (follow-up) and Week 72 (follow-up)", "groups": [{"id": "OG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "405"}, {"groupId": "OG001", "value": "394"}]}], "classes": [{"title": "ADA prevalence", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "ADA incidence", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "ADA positive at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "ADA positive post-baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "ADA pos post-baseline and pos at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "ADA pos post-baseline and not detected at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "ADA not detected post-baseline and pos at baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Persistent Positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Transient Positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Treatment-boosted ADA", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "nAB positive at any visit", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "72 weeks", "description": "Serious and Other (non-serious) adverse event (AE) data is reported for the treatment period, from baseline (Week 0) to end of treatment (Week 52). Treatment-emergent AEs were defined with an onset date \u2265 the first day of IP and \u2264 (the last day of IP + 2 weeks). Patient population was the safety analysis set which included all patients who received at least one dose of IP.\n\nAll-Cause mortality is reported for the overall study period (including the extended follow-up period), up to Week 72.", "eventGroups": [{"id": "EG000", "title": "Tralo 300 mg Q2W", "description": "Tralokinumab 300 mg administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses).", "deathsNumAffected": 1, "deathsNumAtRisk": 425, "seriousNumAffected": 35, "seriousNumAtRisk": 425, "otherNumAffected": 159, "otherNumAtRisk": 425}, {"id": "EG001", "title": "Placebo", "description": "Placebo administered subcutaneously Q2W over a 52-week treatment period (up to 26 doses).", "deathsNumAffected": 4, "deathsNumAtRisk": 422, "seriousNumAffected": 39, "seriousNumAtRisk": 422, "otherNumAffected": 152, "otherNumAtRisk": 422}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Colitis ulcerative", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Haematochezia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Oesophageal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Eosinophilic granulomatosis with polyangiitis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Hepatitis A", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Laryngitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Otitis media acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 422}]}, {"term": "Pulmonary tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Tracheobronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Lumbar vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Patellofemoral pain syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Vascular headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Adnexa uteri pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Uterine haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 17, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 30, "numAffected": 23, "numAtRisk": 422}]}, {"term": "Bronchitis chronic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 422}]}, {"term": "Vitiligo", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 422}]}], "otherEvents": [{"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 93, "numAffected": 23, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 422}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 59, "numAffected": 34, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 50, "numAffected": 31, "numAtRisk": 422}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 49, "numAffected": 29, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 39, "numAffected": 31, "numAtRisk": 422}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 71, "numAffected": 50, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 80, "numAffected": 52, "numAtRisk": 422}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 76, "numAffected": 40, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 49, "numAffected": 32, "numAtRisk": 422}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 51, "numAffected": 35, "numAtRisk": 425}, {"groupId": "EG001", "numEvents": 79, "numAffected": 47, "numAtRisk": 422}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Lead", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com", "phone": "+1 301-398-0582"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-06-09", "uploadDate": "2018-02-23T04:58", "filename": "Prot_000.pdf", "size": 856332}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-10-16", "uploadDate": "2018-02-23T04:58", "filename": "SAP_001.pdf", "size": 2398016}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}